Hydroxycarbamide

Drug Profile

Hydroxycarbamide

Alternative Names: Droxia; Hydrea; Hydroxyurea; Litalir; NSC 32065; OncoCarbide; SQ 1089; WR 83799

Latest Information Update: 24 Jan 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Barr Laboratories; Bristol-Myers Squibb
  • Developer Barr Laboratories; Bristol-Myers Squibb; Teva Pharmaceutical Industries
  • Class Antianaemics; Antineoplastics; Small molecules; Urea compounds
  • Mechanism of Action Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cancer; Sickle cell anaemia
  • Discontinued HIV infections

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 10 Jul 2000 FDA approval for 250mg capsule for cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top